Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gourab Datta

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2017
<sup>11</sup>C-PBR28 and <sup>18</sup>F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple SclerosisGourab Datta, Alessandro Colasanti, Nicola Kalk, et al.
Nature Communications|May 1, 2025
Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical studyAnja Koester, Derrick R Witcher, Mark Lee, et al.
Clinical Pharmacology and Therapeutics|August 29, 2021
First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19Peter Chen, Gourab Datta, Ying Grace Li, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2017
<sup>11</sup>C-PBR28 and <sup>18</sup>F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple SclerosisGourab Datta, Alessandro Colasanti, Nicola Kalk, et al.
Nature Communications|May 1, 2025
Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical studyAnja Koester, Derrick R Witcher, Mark Lee, et al.
Clinical Pharmacology and Therapeutics|August 29, 2021
First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19Peter Chen, Gourab Datta, Ying Grace Li, et al.
Pageof 2